Share
Renée Galá
DexCom, Inc., a global leader in continuous glucose monitoring technology, has appointed Renée Galá to its Board of Directors.
A seasoned executive in the life sciences sector, Ms. Galá brings extensive experience in financial stewardship, strategic growth, and operational leadership. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals, a global biopharmaceutical company that reported over US$4 billion in revenue in 2024. In this role, she oversees a broad spectrum of global functions, including commercial operations, R&D, manufacturing, strategy, and quality.
Prior to becoming President and COO in 2023, Ms. Galá held the role of Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals from 2020 to 2023. Her previous leadership roles include Chief Financial Officer at GRAIL, Inc., a healthcare company focused on early cancer detection, and SVP and CFO at Theravance Biopharma, where she led the company’s spin-out from Theravance, Inc.
Earlier in her career, she held various roles in finance, treasury, and corporate strategy at Eli Lilly and Company, and spent seven years in the energy sector in corporate finance and M&A roles.
Ms. Galá has also contributed her expertise as a board member for several biotech and life sciences companies, including Gossamer Bio, Gyroscope Therapeutics (acquired by Novartis), and Corcept Therapeutics.
She holds a Bachelor of Science in Mathematics from Vanderbilt University and an MBA from Columbia Business School. Her appointment enhances Dexcom’s board with deep financial acumen and a strategic perspective rooted in healthcare innovation and global expansion.
Related posts
